Cargando…

Confirmation of high-throughput screening data and novel mechanistic insights into FXR-xenobiotic interactions by orthogonal assays

Toxicology in the 21st Century (Tox21) is a federal collaboration employing a high-throughput robotic screening system to test 10,000 environmental chemicals. One of the primary goals of the program is prioritizing toxicity evaluations through in vitro high-throughput screening (HTS) assays for larg...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamm, Jon, Mahapatra, Debabrata, Knuth, Megan M., Abedini, Jaleh, Lingerfelt, Mary, Ekins, Sean, Kullman, Seth W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637864/
https://www.ncbi.nlm.nih.gov/pubmed/36353521
http://dx.doi.org/10.1016/j.crtox.2022.100092
_version_ 1784825277439803392
author Hamm, Jon
Mahapatra, Debabrata
Knuth, Megan M.
Abedini, Jaleh
Lingerfelt, Mary
Ekins, Sean
Kullman, Seth W.
author_facet Hamm, Jon
Mahapatra, Debabrata
Knuth, Megan M.
Abedini, Jaleh
Lingerfelt, Mary
Ekins, Sean
Kullman, Seth W.
author_sort Hamm, Jon
collection PubMed
description Toxicology in the 21st Century (Tox21) is a federal collaboration employing a high-throughput robotic screening system to test 10,000 environmental chemicals. One of the primary goals of the program is prioritizing toxicity evaluations through in vitro high-throughput screening (HTS) assays for large numbers of chemicals already in commercial use for which little or no toxicity data is available. Within the Tox21 screening program, disruption in nuclear receptor (NR) signaling represents a particular area of interest. Given the role of NR’s in modulating a wide range of biological processes, alterations of their activity can have profound biological impacts. Farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily that has demonstrated importance in bile acid homeostasis, glucose metabolism, lipid homeostasis and hepatic regeneration. In this study, we re-evaluated 24 FXR agonists and antagonists identified through Tox21 using select orthogonal assays. In transient transactivation assays, 7/8 putative agonists and 4/4 putative inactive compounds were confirmed. Likewise, we confirmed 9/12 antagonists tested. Using a mammalian two hybrid approach we demonstrate that both FXR agonists and antagonists facilitate FXRα-coregulator interactions suggesting that differential coregulator recruitment may mediate activation/repression of FXRα mediated transcription. Additionally, we tested the ability of select FXR agonists and antagonists to facilitate hepatic transcription of FXR gene targets Shp and Bsep in a teleost (Medaka) model. Through application of in vitro cell-based assays, in silico modeling and in vivo gene expressions, we demonstrated the molecular complexity of FXR:ligand interactions and confirmed the ability of diverse ligands to modulate FXRα, facilitate differential coregulator recruitment and activate/repress receptor-mediated transcription. Overall, we suggest a multiplicative approach to assessment of nuclear receptor function may facilitate a greater understanding of the biological and mechanistic complexities of nuclear receptor activities and further our ability to interpret broad HTS outcomes.
format Online
Article
Text
id pubmed-9637864
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-96378642022-11-08 Confirmation of high-throughput screening data and novel mechanistic insights into FXR-xenobiotic interactions by orthogonal assays Hamm, Jon Mahapatra, Debabrata Knuth, Megan M. Abedini, Jaleh Lingerfelt, Mary Ekins, Sean Kullman, Seth W. Curr Res Toxicol Articles from the special issue PMC Invite 2021-2022 Toxicology in the 21st Century (Tox21) is a federal collaboration employing a high-throughput robotic screening system to test 10,000 environmental chemicals. One of the primary goals of the program is prioritizing toxicity evaluations through in vitro high-throughput screening (HTS) assays for large numbers of chemicals already in commercial use for which little or no toxicity data is available. Within the Tox21 screening program, disruption in nuclear receptor (NR) signaling represents a particular area of interest. Given the role of NR’s in modulating a wide range of biological processes, alterations of their activity can have profound biological impacts. Farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily that has demonstrated importance in bile acid homeostasis, glucose metabolism, lipid homeostasis and hepatic regeneration. In this study, we re-evaluated 24 FXR agonists and antagonists identified through Tox21 using select orthogonal assays. In transient transactivation assays, 7/8 putative agonists and 4/4 putative inactive compounds were confirmed. Likewise, we confirmed 9/12 antagonists tested. Using a mammalian two hybrid approach we demonstrate that both FXR agonists and antagonists facilitate FXRα-coregulator interactions suggesting that differential coregulator recruitment may mediate activation/repression of FXRα mediated transcription. Additionally, we tested the ability of select FXR agonists and antagonists to facilitate hepatic transcription of FXR gene targets Shp and Bsep in a teleost (Medaka) model. Through application of in vitro cell-based assays, in silico modeling and in vivo gene expressions, we demonstrated the molecular complexity of FXR:ligand interactions and confirmed the ability of diverse ligands to modulate FXRα, facilitate differential coregulator recruitment and activate/repress receptor-mediated transcription. Overall, we suggest a multiplicative approach to assessment of nuclear receptor function may facilitate a greater understanding of the biological and mechanistic complexities of nuclear receptor activities and further our ability to interpret broad HTS outcomes. Elsevier 2022-11-01 /pmc/articles/PMC9637864/ /pubmed/36353521 http://dx.doi.org/10.1016/j.crtox.2022.100092 Text en © 2022 The Authors. Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles from the special issue PMC Invite 2021-2022
Hamm, Jon
Mahapatra, Debabrata
Knuth, Megan M.
Abedini, Jaleh
Lingerfelt, Mary
Ekins, Sean
Kullman, Seth W.
Confirmation of high-throughput screening data and novel mechanistic insights into FXR-xenobiotic interactions by orthogonal assays
title Confirmation of high-throughput screening data and novel mechanistic insights into FXR-xenobiotic interactions by orthogonal assays
title_full Confirmation of high-throughput screening data and novel mechanistic insights into FXR-xenobiotic interactions by orthogonal assays
title_fullStr Confirmation of high-throughput screening data and novel mechanistic insights into FXR-xenobiotic interactions by orthogonal assays
title_full_unstemmed Confirmation of high-throughput screening data and novel mechanistic insights into FXR-xenobiotic interactions by orthogonal assays
title_short Confirmation of high-throughput screening data and novel mechanistic insights into FXR-xenobiotic interactions by orthogonal assays
title_sort confirmation of high-throughput screening data and novel mechanistic insights into fxr-xenobiotic interactions by orthogonal assays
topic Articles from the special issue PMC Invite 2021-2022
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637864/
https://www.ncbi.nlm.nih.gov/pubmed/36353521
http://dx.doi.org/10.1016/j.crtox.2022.100092
work_keys_str_mv AT hammjon confirmationofhighthroughputscreeningdataandnovelmechanisticinsightsintofxrxenobioticinteractionsbyorthogonalassays
AT mahapatradebabrata confirmationofhighthroughputscreeningdataandnovelmechanisticinsightsintofxrxenobioticinteractionsbyorthogonalassays
AT knuthmeganm confirmationofhighthroughputscreeningdataandnovelmechanisticinsightsintofxrxenobioticinteractionsbyorthogonalassays
AT abedinijaleh confirmationofhighthroughputscreeningdataandnovelmechanisticinsightsintofxrxenobioticinteractionsbyorthogonalassays
AT lingerfeltmary confirmationofhighthroughputscreeningdataandnovelmechanisticinsightsintofxrxenobioticinteractionsbyorthogonalassays
AT ekinssean confirmationofhighthroughputscreeningdataandnovelmechanisticinsightsintofxrxenobioticinteractionsbyorthogonalassays
AT kullmansethw confirmationofhighthroughputscreeningdataandnovelmechanisticinsightsintofxrxenobioticinteractionsbyorthogonalassays